Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment

Trial Profile

Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms SCLERADEC II
  • Most Recent Events

    • 14 Jun 2017 According to a Cytori Therapeutics media release, updates from the study will be presented at the Annual European Congress of Rheumatology (EULAR 2017).
    • 10 Jan 2017 According to a Cytori Therapeutics media release, completion of enrollment in this trail is anticipated in mid-2017 with data unblinding and analysis estimated to occur by the end of 2017.
    • 30 May 2016 According to the information on the company website, the results from this and the US STAR trial (700271953) will be used to obtain EU conditional marketing authorisation and normal marketing authorisation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top